Secondary malignancies in non‐Hodgkin lymphoma survivors: 40 years of follow‐up assessed by treatment modality
Open Access
- 17 August 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (3) , 2624-2636
Abstract
Background: Survivors of non‐Hodgkin lymphoma (NHL) have increased secondary malignancy (SM) risk. We quantified this risk by patient and treatment factors.Methods: Standardized incidence ratios (SIR, observed‐to‐expected [O/E] ratio) were assessed in 142,637 NHL patients diagnosed from 1975 to 2016 in the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Comparisons were made between subgroups in terms of their SIRs relative to respective endemic populations.Results: In total, 15,979 patients developed SM, more than the endemic rate (O/E 1.29; p < 0.05). Compared with white patients, relative to respective endemic populations, ethnic minorities had a higher risk of SM (white O/E 1.27, 95% CI 1.25–1.29; black O/E 1.40, 95% CI 1.31–1.48; other O/E 1.59, 95% CI 1.49–1.70). Relative to respective endemic populations, patients who received radiotherapy had similar SM rates to those who did not (O/E 1.29 each), but irradiated patients had increased breast cancer (p < 0.05). Patients who received chemotherapy had higher SM rates than those who did not (O/E 1.33 vs. 1.24, p < 0.05) including more leukemia, Kaposi sarcoma, kidney, pancreas, rectal, head and neck, and colon cancers (p < 0.05).Conclusions: This is the largest study to examine SM risk in NHL patients with the longest follow‐up. Treatment with radiotherapy did not increase overall SM risk, while chemotherapy was associated with a higher overall risk. However, certain subsites were associated with a higher risk of SM, and they varied by treatment, age group, race and time since treatment. These findings are helpful for informing screening and long‐term follow‐up in NHL survivors.Keywords
This publication has 38 references indexed in Scilit:
- Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II InhibitorInternational Journal of Environmental Research and Public Health, 2012
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up studyHaematologica, 2008
- The risk of secondary malignancies over 30 years after the treatment of non‐Hodgkin lymphomaCancer, 2006
- Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patientsBlood, 2003
- Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma PatientsJournal of Clinical Oncology, 2003
- Radiation and breast carcinogenesis*Medical and Pediatric Oncology, 2001
- Myeloid leukemia after hematotoxins.Environmental Health Perspectives, 1996
- Bladder Cancer after Chemotherapy for Non-Hodgkin's LymphomaNew England Journal of Medicine, 1989
- Carcinoma of the Urinary Bladder after Treatment with Cyclophosphamide for Non-Hodgkin's LymphomaNew England Journal of Medicine, 1988